Home PD - Search Results

1

Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.

Home PD, McCrimmon RJ, Rosenstock J, Blüher M, Pegelow K, Melas-Melt L, Djaballah K, Giorgino F; SoliMix trial investigators. Home PD, et al. Diabetes Obes Metab. 2023 Mar;25(3):656-663. doi: 10.1111/dom.14907. Epub 2022 Nov 23. Diabetes Obes Metab. 2023. PMID: 36309941 Free PMC article.

2

Making sense of weekly insulins.

Home P. Home P. Lancet Diabetes Endocrinol. 2023 Mar;11(3):140-141. doi: 10.1016/S2213-8587(23)00002-5. Epub 2023 Feb 6. Lancet Diabetes Endocrinol. 2023. PMID: 36758573 No abstract available.

3

Insulin biobetters and biosimilars in clinical practice.

Home P. Home P. J R Coll Physicians Edinb. 2023 Jun;53(2):147-155. doi: 10.1177/14782715231173770. Epub 2023 May 18. J R Coll Physicians Edinb. 2023. PMID: 37198930 Free article. Review.

4

Lingering Effects of Hyperglycemia in Recently Diagnosed Diabetes During Long-term Follow-up of the DCCT/EDIC and UKPDS Cohorts: More Evidence That Early Control Matters.

Riddle MC, Gerstein HC, Home PD. Riddle MC, et al. Among authors: home pd. Diabetes Care. 2021 Sep 21:dci210030. doi: 10.2337/dci21-0030. Online ahead of print. Diabetes Care. 2021. PMID: 34548282 No abstract available.

5

Insulin therapy development beyond 100 years.

Home PD, Mehta R. Home PD, et al. Lancet Diabetes Endocrinol. 2021 Oct;9(10):695-707. doi: 10.1016/S2213-8587(21)00182-0. Epub 2021 Sep 1. Lancet Diabetes Endocrinol. 2021. PMID: 34480874 Review.

6

Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.

Home PD, Mehta R, Hafidh KAS, Gurova OY, Alvarez A, Serafini P, Pourrahmat MM. Home PD, et al. Diabetes Obes Metab. 2021 Dec;23(12):2660-2669. doi: 10.1111/dom.14518. Epub 2021 Aug 31. Diabetes Obes Metab. 2021. PMID: 34402153 Free PMC article.

7

Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.

Home PD, Aroda VR, Blonde L, Guyot P, Shaunik A, Fazeli MS, Goswami H, Kalra S, Pourrahmat MM. Home PD, et al. Diabetes Obes Metab. 2020 Nov;22(11):2170-2178. doi: 10.1111/dom.14136. Epub 2020 Jul 26. Diabetes Obes Metab. 2020. PMID: 32627297

8

Comparison of Multiple Cut Points for Time in Range in Relation to Risk of Abnormal Carotid Intima-Media Thickness and Diabetic Retinopathy.

Lu J, Home PD, Zhou J. Lu J, et al. Among authors: home pd. Diabetes Care. 2020 Aug;43(8):e99-e101. doi: 10.2337/dc20-0561. Epub 2020 Jun 11. Diabetes Care. 2020. PMID: 32527796 No abstract available.

9

Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.

Bolli GB, Landgraf W, Bosnyak Z, Melas-Melt L, Home PD. Bolli GB, et al. Among authors: home pd. Diabetes Obes Metab. 2020 Sep;22(9):1664-1669. doi: 10.1111/dom.14065. Epub 2020 May 29. Diabetes Obes Metab. 2020. PMID: 32314521 Free PMC article.

10

Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.

Owens DR, Landgraf W, Frier BM, Zhang M, Home PD, Meneghini L, Bolli GB. Owens DR, et al. Among authors: home pd. Diabetes Obes Metab. 2019 Feb;21(2):321-329. doi: 10.1111/dom.13607. Diabetes Obes Metab. 2019. PMID: 30520217 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

225 results

Search Page

Filters